This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | C62 (C62.0 undescended testis, C62.1 descended testis, C62.9 testis, unspecified) |
| B. Synonyms | Testicular cancer, testicular germ cell tumor (GCT: Germ Cell Tumor), Seminoma, nonseminomatous germ cell tumor (NSGCT), Embryonal carcinoma, Teratoma, Yolk sac tumor |
| C. Adult onset | Not low — mainly occurs in the 20s–40s — The most common solid malignancy in men aged 15–35. In Korea, the 5-year survival rate is 94.2%, the highest among urologic malignancies. Cure rate is very high with early detection. |
| Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5% | |
The history of treating testicular cancer (germ cell tumors) is one of the greatest success stories of modern oncology. Until the mid-20th century, metastatic testicular cancer was a fatal disease, but the introduction of cisplatin-based chemotherapy, developed in 1965 by Lawrence Einhorn and colleagues, changed the course of treatment. In the mid-1970s, Einhorn established the BEP (bleomycin, etoposide, cisplatin) regimen, achieving cure in more than 80% of metastatic testicular cancers, which is recorded as the most dramatic treatment success in the history of oncology.
Before that era, radiotherapy was the main treatment for seminoma. After seminoma was found to be radiosensitive in the 1920s–30s, radiotherapy was used for decades as adjuvant treatment for early seminoma. However, with the advent of BEP chemotherapy and retroperitoneal lymph node dissection (RPLND), radiotherapy came to be used only in a limited way for certain localized lesions.
In Korea, testicular cancer is relatively rare among urologic malignancies, but it has great social significance as the most common solid tumor in young men aged 15–35. The incidence of testicular cancer in Korea is reported as a crude incidence rate of 0.5% in 2015 and an age-standardized incidence rate of 1.3% in 2018. The 5-year survival rate of testicular cancer in Koreans is 94.2%, the highest among urologic malignancies, reflecting the outstanding efficacy of BEP-based treatment.
The best-established risk factor for testicular germ cell tumors is cryptorchidism (undescended testis). In patients with cryptorchidism, the risk of testicular cancer is increased 4–10-fold compared with the general population, and about 10% of all testicular cancer patients have a history of cryptorchidism. An abdominal undescended testis carries a higher risk than an inguinal one, and early corrective orchiopexy (before age 5–6) reduces but does not eliminate the risk.
Klinefelter syndrome (47XXY) is a genetic condition that increases the risk of testicular cancer, particularly extragonadal tumors (such as mediastinal GCT). A personal or family history of testicular cancer is also an important risk factor; having a first-degree relative with testicular cancer increases the risk 4–10-fold. Existing germ cell neoplasia in situ (GCNIS) in the contralateral testis is also a risk factor.
Other risk factors include low birth weight, advanced maternal age, being a twin (especially in dizygotic twins, where GCT in one twin increases the risk in the other), White race, and residence in developed countries. HIV infection also increases the risk of seminoma. An association with occupational exposure (herbicides, pesticides, etc.) has been suggested but not yet established. Interestingly, testicular cancer incidence is high in high-income countries and Northern Europe, suggesting a possible role of environmental and endocrine-disrupting substances.
Testicular germ cell tumors have unique genetic features. Isochromosome of the short arm of chromosome 12 (isochromosome 12p, i(12p)) is found in more than 90% and is used as a molecular marker of GCT. i(12p) causes amplification of oncogenes such as CCND2, KRAS and CCND2.
Molecular abnormalities differ by histologic type. In Seminoma, KIT gene mutation or amplification (12q22; in 25–30%) is most characteristic, and RAS pathway (KRAS, NRAS) variants are also observed. KIT variants cause constitutive activation of the KIT receptor tyrosine kinase, sustaining stem cell proliferation signals. In nonseminomatous GCT (NSGCT), KIT variants are rare, and variants in KRAS, TP53, SMAD4, PTEN and others are observed variably depending on the direction of differentiation.
Gonadoblastoma associated with disorders of sex development (DSD) is linked to risk related to the TSPY (testis-specific protein Y-encoded) gene located at the gonadoblastoma locus on the Y chromosome (GBY). Familial testicular cancer is rare, and GWAS findings are accumulating that polymorphisms in KITLG (kit ligand), SPRY4, BAK1, DMRT1, TERT and others are associated with GCT susceptibility in the general population. Overall, GCTs have a relatively low somatic mutation burden, but chromosomal copy number changes such as i(12p) act as the main oncogenic mechanism.
Testicular cancer is the most common malignancy in men aged 15–44. About 74,000 new cases are diagnosed worldwide each year. Incidence is highest in Northern Europe (Norway, Denmark) (8–10 cases per 100,000 population) and lowest in Asia and Africa (0.5–2 cases). Over the past 50 years, incidence has more than doubled in many developed countries, which may be related to diet, environmental endocrine-disrupting substances (endocrine disruptors, plasticizers, pesticides) and lifestyle changes.
Korea has traditionally had a lower incidence than Western countries, but it is gradually increasing. A crude incidence rate of 0.5% in 2015 and an age-standardized incidence rate of 1.3% in 2018 are reported. A Korean study based on National Health Insurance data has also reported an increased risk of testicular cancer in patients with sleep apnea (OSA). By histologic type, about 50–60% of all GCTs are pure seminoma, and the rest are NSGCT or mixed type. In children, yolk sac tumor and teratoma predominate, showing a pathologic pattern different from adults.
Testicular GCT begins with failure of normal differentiation of fetal germ cells (primordial germ cells, PGCs) or gonocytes. Normally, PGCs migrate along the genital ridge and differentiate into spermatogonia; when this process is disrupted, germ cell neoplasia in situ (GCNIS) cells accumulate. GCNIS cells are immature cells expressing pluripotency markers such as OCT3/4, NANOG and SOX17, and are the precursor cells of invasive GCT.
Amplification of 12p genes by i(12p) promotes the transition from GCNIS to invasive tumor. The KIT/KITLG signaling pathway is essential for germ cell proliferation and survival, and KIT mutation or KITLG overexpression is a key oncogenic mechanism of seminoma. KIT signaling promotes cell cycle progression through the RAS-MAPK and PI3K-AKT pathways. The local testicular environment (blood-testis barrier, growth factor secretion by Sertoli cells) also influences tumor development and progression. The increased temperature in an undescended testis causes germ cell DNA damage and impaired spermatogenesis, which is presumed to be the direct cause of the increased GCT risk.
The most common symptom of testicular cancer is a painless testicular mass or intrascrotal swelling. Patients often notice a "hardened testis" or "something feeling different," and because it is usually painless, many do not suspect cancer and leave it for months. Some may complain of scrotal heaviness, dull pain, or intrascrotal discomfort.
In about 10%, it is misdiagnosed as acute epididymo-orchitis and treated with antibiotics, and testicular cancer is diagnosed late when there is no improvement. With metastatic disease, back or abdominal pain from retroperitoneal lymphadenopathy, cough and dyspnea from lung metastasis, and headache and neurologic symptoms from brain metastasis may occur. Rarely, gynecomastia develops with β-hCG-producing tumors (NSGCT containing a choriocarcinoma component). Testicular cancer arising in an undescended testis may first present as an intra-abdominal or inguinal mass.
On physical examination, a firm, painless intratesticular mass is palpated. A normal testis has a soft, uniform texture, whereas a tumor appears as a firm nodule within the testicular parenchyma or hardening of the entire testis. On transillumination, a hydrocele transmits light but a solid tumor blocks it. This distinguishes a solid intratesticular mass from a hydrocele.
Tumor marker testing is key to diagnosis and staging. α-fetoprotein (AFP) is elevated in yolk sac tumor and embryonal carcinoma and is normal in adult seminoma. β-hCG is elevated with a choriocarcinoma component and in some seminomas. LDH (lactate dehydrogenase) is a nonspecific marker related to stage and tumor burden. AFP, β-hCG and LDH are core elements of the IGCCCG prognostic classification and are also used for treatment monitoring. Testicular ultrasound shows a hypoechoic or mixed-echo intratesticular mass, with sensitivity approaching 100%.
Standard population screening for testicular cancer is currently not recommended. Because incidence is low, most cases are symptomatic early (palpable mass), and treatment is highly effective, the additional benefit of screening is limited. However, in high-risk groups (history of cryptorchidism, history of contralateral testicular cancer, family history), regular testicular self-examination (TSE) is taught and recommended.
Testicular self-examination is a method of checking oneself for changes in testicular size, shape and texture once a month after a warm bath. Patients are taught to visit a urologist immediately if a firm nodule, enlargement or hardening of one testis, or intrascrotal discomfort persists. Patients with cryptorchidism should maintain periodic lifelong self-examination, including the normal contralateral testis, even after early corrective surgery. Because the risk of a metachronous tumor in the contralateral testis after cure of testicular cancer is about 2%, long-term follow-up is needed.
The first step in diagnosing testicular cancer is scrotal ultrasound. A hypoechoic intratesticular mass with abundant blood flow strongly suggests malignancy and is differentiated from benign conditions such as epididymitis. When testicular cancer is clinically suspected, radical orchidectomy via inguinal approach is performed before CT or MRI, providing the definitive diagnosis while removing the primary lesion. A scrotal approach (scrotal incision) is absolutely contraindicated because it alters the lymphatic drainage pathway and increases the risk of local recurrence.
Tumor markers (AFP, β-hCG, LDH) are measured before surgery and followed after surgery according to their half-lives to confirm normalization (AFP half-life 5–7 days, β-hCG half-life 24–36 hours). Abdominal, pelvic and chest CT is performed for staging, with brain MRI added if brain metastasis is suspected. Staging uses the AJCC TNM classification together with the IGCCCG (International Germ Cell Cancer Collaborative Group) prognostic classification, dividing patients into Good, Intermediate and Poor prognosis groups.
Treatment is determined by histologic type and stage. At all stages, inguinal radical orchidectomy is the primary treatment. In stage I seminoma, the choice is between one cycle of adjuvant carboplatin alone and surveillance; radiotherapy is gradually being used less because of concerns about late toxicity. In stage I NSGCT, surveillance, nerve-sparing RPLND (retroperitoneal lymph node dissection), or one cycle of BEP is chosen according to risk and patient preference.
In metastatic GCT (stage II–III), BEP (bleomycin, etoposide, cisplatin) chemotherapy is standard. By prognostic group, 3 cycles of BEP are recommended for the good group and 4 cycles for the intermediate and poor groups. In NSGCT with a residual mass after BEP, resection of residual tumor (post-chemotherapy RPLND or resection) is performed to remove mature teratoma or small amounts of viable cancer cells. In relapsed or refractory GCT, salvage chemotherapy with TIP (paclitaxel, ifosfamide, cisplatin) or VeIP (vinblastine, ifosfamide, cisplatin), as well as high-dose chemotherapy + autologous hematopoietic stem cell transplantation, is selectively performed. In seminoma, further treatment can be omitted if the residual mass is FDG-PET negative.
Testicular GCT is one of the most curable solid malignancies, with cure possible in more than 80% even with metastatic disease.
| Prognostic group (IGCCCG) | Distribution (%) | 5-year event-free survival |
|---|---|---|
| Good | 56% | 91% |
| Intermediate | 28% | 79% |
| Poor | 16% | 48% |
The 5-year survival rate for localized disease (stage I) is nearly 100%, and the overall 5-year survival rate for testicular cancer in Korea is 94.2%, the highest among urologic malignancies. Seminoma is more sensitive to radiotherapy and chemotherapy than NSGCT and generally has a favorable prognosis. Adverse prognostic factors include non-pulmonary visceral metastases (non-pulmonary visceral metastases), AFP >10,000 ng/mL, β-hCG >50,000 IU/L, and LDH >10× the upper limit of normal. Long-term follow-up is needed after treatment for long-term chemotherapy-related complications (ototoxicity, nephrotoxicity, platinum-related cardiovascular risk).
The most important preventive measure for testicular cancer is early detection and correction of cryptorchidism. Cryptorchidism is identified at newborn screening, and if spontaneous descent does not occur, orchidopexy should be performed between 6 and 18 months of age. Early correction does not eliminate testicular cancer risk but significantly reduces it and makes palpation examination easier should a tumor develop later.
In high-risk groups (history of cryptorchidism, family history, Klinefelter syndrome, prior GCT), regular testicular self-examination increases the likelihood of early detection. A culture of and education on reporting firm, painless testicular changes to a medical facility early are important. From an environmental prevention standpoint, minimizing exposure to endocrine-disrupting substances (bisphenol A, phthalates, pesticides, etc.) during pregnancy may be associated with reducing GCT development. To date, there is no established drug prevention or specific dietary prevention strategy, and in the long term, research on the mechanisms of GCT development and the development of risk prediction models using high-risk genetic markers are under way.